Semaglutide 4-week results: what actually changes in the first month

What the first four weeks are really for

The decision many people face at the four-week mark is whether anything is 'working'. It's a fair question, and the honest answer is that the first month has a specific job that isn't visible on the scales.

Semaglutide (licensed for weight management in the UK as Wegovy) is a GLP-1 receptor agonist. It mimics a gut hormone involved in appetite regulation and slows gastric emptying. The clinical schedule starts at 0.25mg weekly. That dose isn't where the therapeutic weight loss happens; it's where your digestive system learns to tolerate the medicine. Think of it as the body doing necessary groundwork.

What you might notice at four weeks is subtler: meals that feel finished sooner, snacks you didn't reach for, a quieter sense of hunger than you've been used to. Those signals suggest the mechanism is active, even if the number on the scales has barely shifted. If you're curious about what semaglutide results in the first week tend to look like, it helps to set realistic expectations before drawing any conclusions at the four-week point. A useful checking habit: at the end of each week, note whether you left food on your plate more than once. That small observation tells you more about early progress than the scales do at this stage.

The week-by-week picture of semaglutide results shows that changes compound over time, particularly once the dose increases.

What clinical evidence says about early versus later results

The STEP 1 trial (published in the New England Journal of Medicine) followed 1,961 adults with obesity over 68 weeks at a 2.4mg maintenance dose. Average weight loss across the full trial was around 15% of starting body weight. That figure did not arrive in four weeks.

Early weight change in semaglutide trials tends to be in the range of 1–3% of body weight by week four, depending on starting weight, diet and individual response. Some people see slightly more; others see less and go on to achieve strong results later. The dose escalation (0.25mg, then 0.5mg, then 1.0mg, onward to 2.4mg) is the mechanism by which results build. Each step takes roughly four weeks, so at the one-month mark almost everyone is still at the beginning of that journey.

For context on how the picture develops beyond this point, the eight-week results page covers what typically changes once the first dose increase has taken effect.

Side effects in the first four weeks: what's normal

The side-effect profile at four weeks is often the thing people remember most vividly. Nausea is the most commonly reported early experience — not universal, but frequent. It tends to peak in the first day or two after an injection and ease before the next dose. Constipation, loose stools, mild indigestion and a general fatigue are also reported in this window.

The NHS semaglutide page sets out the full common-side-effect list clearly, and is worth bookmarking during the first month. Most GI effects are self-limiting and settle as the body adjusts, though everyone's timeline differs.

There are symptoms that warrant prompt medical attention: severe, persistent stomach pain that travels toward the back can be a sign of pancreatitis, which is a rare but serious side effect associated with GLP-1 medicines. If that happens, stop the injection and seek medical help promptly. You can also report any suspected side effects via the MHRA Yellow Card scheme.

If you are considering what to expect before starting, the guide on how long Wegovy takes to work gives a fuller timeline across the titration schedule.

The decision at four weeks: stick with it, or worry?

Most people who don't see dramatic scale movement at four weeks are not experiencing failure, they are experiencing the normal first chapter. The decision worth making at this point is not 'is this working?' but 'am I giving it a fair chance?'. That means continuing alongside the dietary and activity habits agreed with your prescriber, watching for the appetite signals described above, and not increasing or skipping doses based on impatience.

Where it's worth flagging things to a prescriber: side effects that are severe enough to affect daily life and aren't easing; no appetite change at all by the end of week four; or any of the urgent symptoms above. Our clinical team is reachable seven days a week for aftercare questions, and you can read more about the team's approach on the clinical team page.

For people who are weighing up how long they're prepared to commit, it's also worth knowing that discontinuing semaglutide usually reverses the weight-management effect over time. The guidance on breaks from Wegovy covers what the evidence shows.

If you're at the stage of thinking about starting a clinically supervised weight-loss treatment, speaking to our prescribers is the right first step. Semaglutide requires a prescription, and a GPhC-registered clinician reviews every consultation personally before any treatment is issued.